CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.88BUSDvs all stocks (USD)
Revenue (TTM)
670.00MUSDvs all stocks (USD)
Profit Margin
-90.90%vs Biotechnology peers
Beta
0.3070xvs all stocks
52-Week Change
10.95%vs all stocks
Market Capitalization
2.88BUSDvs all stocks (USD)
Enterprise Value
3.67BUSDvs all stocks (USD)
Forward P/E
18.89xvs Biotechnology peers
Price to Sales (TTM)
4.30xvs Biotechnology peers
Enterprise to Revenue
5.48xvs Biotechnology peers
Enterprise to EBITDA
-7.38xvs Biotechnology peers
Gross Margin
77.94%vs Biotechnology peers
Profit Margin
-90.90%vs Biotechnology peers
Operating Margin
-102.21%vs Biotechnology peers
Return on Assets (TTM)
-25.45%vs Biotechnology peers
Revenue (TTM)
670.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.72USDUpdated Jul 19, 2026Quarterly Revenue Growth
-2.20%vs Biotechnology peers
Gross Profit (TTM)
-188.00MUSDvs all stocks (USD)
EBITDA (TTM)
-497.00MUSDvs all stocks (USD)
Net Income (TTM)
-609.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.36%vs Biotechnology peers
Operating Cash Flow (TTM)
-497.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-219.09MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
7.00MUSDFY2025 · Dec 31, 2025Revenue
673.00MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
109.00MUSDFY2025 · Dec 31, 2025Gross Profit
564.00MUSDFY2025 · Dec 31, 2025Operating Income
-535.00MUSDvs all stocks (USD)
Pre-tax Income
-571.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.00MUSDFY2025 · Dec 31, 2025Net Income
-575.00MUSDFY2025 · Dec 31, 2025EBIT
-509.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-474.00MUSDFY2025 · Dec 31, 2025Research & Development
750.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
349.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
25.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
62.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
-5.83USDFY2025 · Dec 31, 2025EPS (Diluted)
-5.83USDFY2025 · Dec 31, 2025Basic Shares Outstanding
98.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
98.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-575.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-452.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
-458.00MUSDDerived from operating cash flow minus capital expenditure. This filing charges 35M of depreciation against 6M of capital expenditure, and its own free-cash-flow line reads -487M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
436.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-575.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
35.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
153.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-52.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-31.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
24.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.00MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-15.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-186.00MUSDFY2025 · Dec 31, 2025Sale of Investments
444.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
251.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
392.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
478.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
98.32MSharesUpdated Jul 19, 2026Float Shares
94.51MSharesUpdated Jul 19, 2026Shares Short
16.22MSharesUpdated Jul 19, 2026Short Ratio
5.36daysvs all stocks
Short % of Shares Outstanding
17.03%vs all stocks
% Held by Insiders
3.45%vs all stocks
% Held by Institutions
101.78%vs all stocks
Total Cash (MRQ)
413.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.21USDUpdated Jul 19, 2026Total Debt (MRQ)
1.20BUSDvs all stocks (USD)
Current Ratio (MRQ)
2.02xvs Biotechnology peers
Book Value per Share (MRQ)
-2.41USDUpdated Jul 19, 2026Total Assets
951.00MUSDvs all stocks (USD)
Total Current Assets
951.00MUSDFY2025 · Dec 31, 2025Total Liabilities
1.60BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.22BUSDFY2025 · Dec 31, 2025Total Current Liabilities
384.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
421.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
259.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
158.00MUSDFY2025 · Dec 31, 2025Inventory
52.00MUSDFY2025 · Dec 31, 2025Accounts Payable
31.00MUSDFY2025 · Dec 31, 2025Short-term Debt
12.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
76.00MUSDFY2025 · Dec 31, 2025Long-term Debt
24.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
20.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-4.53BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-73.00MUSDvs all stocks (USD)
Treasury Stock
8.00MUSDFY2025 · Dec 31, 202552-Week Low
18.29USDUpdated Jul 19, 202652-Week High
39.89USDUpdated Jul 19, 202652-Week Change
10.95%vs all stocks
Beta
0.3070xvs all stocks
50-Day MA
27.16USDUpdated Jul 19, 2026200-Day MA
27.22USDUpdated Jul 19, 2026Avg 10-Day Volume
1.91MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.68MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-6.10USDUpdated Jul 19, 2026Other Income / Expense
1.00MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: -0.91
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Piramal Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
PLANET LABS PBC
3 interpretationsRevenue Growing With Receivables GrowingPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Molina Healthcare Inc.
2 interpretationsRevenue Growing With Receivables GrowingPartial Recovery After Sharp Decline
Sanil Electric Co. Ltd.
2 interpretationsRevenue Growing With Receivables GrowingPartial Recovery After Sharp Decline